Table 2 Comparison of changes in vision and central retinal thickness: baseline vs 1 year and subgroup analyses

From: Efficacy and timing of adjunctive therapy in the anti-VEGF treatment regimen for macular oedema in retinal vein occlusion: 12-month real-world result

  Total RVO, n=66 CRVO, n=29 HRVO, n=9 BRVO, n=28
Comparison of visual acuity (VA) in LogMAR (Snellen equivalent)
 Baseline: median VA (IQR) 0.71 (6/30) (0.43–1.16) 1.00 (6/60) (0.52–1.41) 0.72 (6/30) (0.41–1.05) 0.60 (6/24) (0.3–0.78)
aPostloading: median VA (IQR) 0.48 (6/18) (0.18–0.84)    
  P<0.001    
 One year: median VA (IQR) 0.48 (6/18) (0.18–0.78) 0.78 (6/36) (0.48–1.14) 0.44 (6/15) (0.15–0.54) 0.54 (6/20) (0.30–0.78)
  P<0.001 P=0.055 P=0.033 P<0.001
One year of visual changes
 Worse 10 (15%) 8 (28%) 1 (11%) 1 (4%)
 Stable 5 (8%) 2 (7%) 1 (11%) 3 (11%)
 Improved 51 (77%) 19 (66%) 7 (78%) 17 (61%)
 Improved by 3 lines 34 (52%) 13 (45%) 4 (44%) 16 (57%)
 Achieved 6/12 or better 30 (45.5%)    
Comparison of central retinal thickness (CRT) changes in μm
 Baseline: median CRT (IQR) 531 (435–622) 571 (466–663) 513 (430–559) 499 (403–553)
aPost loading: median CRT (IQR) 239 (215–290)    
  P<0.001    
 One year: median CRT (IQR) 245 (221–351) 236 (208–332) 285 (243–386) 252 (224–347)
  P<0.001 P<0.001 P=0.009 P<0.001
  1. Abbreviations: BRVO, branch retinal vein occlusion; IQR, interquartile-range (statistical analysis using Wilcoxon signed-rank test); CRVO, central retinal vein occlusion; HRVO, hemi-retinal vein occlusion; RVO, retinal vein occlusion.
  2. aSubgroup analyses on VA and CRT were not performed in the postloading phase.